Abstract:Cumulative evidence has established that Interferon (IFN)-γ has both pathogenic and protective roles in Multiple Sclerosis and the animal model, Experimental Autoimmune Encephalomyelitis (EAE). However, the underlying mechanisms to the beneficial effects of IFN-γ are not well understood. In this study, we found that IFN-γ exerts therapeutic effects on chronic, relapsing-remitting, and chronic progressive EAE models. The frequency of regulatory T (Treg) cells in spinal cords from chronic EAE mice treated with IFN-γ was significantly increased with no effect on Th1 and Th17 cells. Consistently, depletion of FOXP3-expressing cells blocked the protective effects of IFN-γ, indicating that the therapeutic effect of IFN-γ depends on the presence of Treg cells. However, IFN-γ did not trigger direct in vitro differentiation of Treg cells. In vivo administration of blocking antibodies against either interleukin (IL)-10, transforming growth factor (TGF)-β or program death (PD)-1, revealed that the protective effects of IFN-γ in EAE were also dependent on TGF-β and PD-1, but not on IL-10, suggesting that IFN-γ might have an indirect role on Treg cells acting through antigen-presenting cells. Indeed, IFN-γ treatment increased the frequency of a subset of splenic CD11b + myeloid cells expressing TGF-β-Latency Associated Peptide (LAP) and program death ligand 1 (PD-L1) in a signal transducer and activator of transcription (STAT)-1-dependent manner. Furthermore, splenic CD11b + cells from EAE mice preconditioned in vitro with IFN-γ and myelin oligodendrocyte glycoprotein (MOG) peptide exhibited a tolerogenic phenotype with the capability to induce conversion of naïve CD4 + T cells mediated by secretion of TGF-β. Remarkably, adoptive transfer of splenic CD11b + cells from IFN-γ-treated EAE mice into untreated recipient mice ameliorated clinical symptoms of EAE and limited central nervous system infiltration of mononuclear cells and effector helper T cells. These results reveal a novel cellular and molecular mechanism whereby IFN-γ promotes beneficial effects in EAE by endowing splenic CD11b + myeloid cells with tolerogenic and therapeutic activities.

A Serine Protease Inhibitor Induces Type 1 Regulatory T Cells Through IFN-γ/STAT1 Signaling

TGF-β–Induced Regulatory T Cells Directly Suppress B Cell Responses Through a Noncytotoxic Mechanism

A Serine Protease Inhibitor Suppresses Autoimmune Neuroinflammation by Activating the STING/IFN-βaxis in Macrophages

Bowman Birk Protease Inhibitor Suppresses Gm-Csf, Th17 Cells and Cns Autoimmune Inflammatory Demyelination

Bowman-Birk Protease Inhibitor Induces Tr1 Cells And Suppress Effector Phase Of EAE Disease; A Potential NOVEL Therapy For Multiple Sclerosis (P1.183)

Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor.

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

Bowman–Birk Inhibitor Attenuates Experimental Autoimmune Encephalomyelitis by Delaying Infiltration of Inflammatory Cells into the CNS

The Role of STAT3 in Antigen-Igg Inducing Regulatory CD4+Foxp3+T Cells

B7H1-Ig Fusion Protein Activates the CD4+ IFN-γ Receptor+ Type 1 T Regulatory Subset through IFN-γ-Secreting Th1 Cells

Suppressive Effect of Il-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis

Cutting Edge: TLR3 Stimulation Suppresses Experimental Autoimmune Encephalomyelitis by Inducing Endogenous IFN-beta.

B7H1-Ig fusion protein activates the CD4(+) IFN-gamma receptor(+) type 1 T regulatory subset through IFN-gamma-secreting Th1 cells

Interferonγ and IL-27 positively regulate type 1 regulatory T-cell development during adaptive tolerance

Neutralization of IL-4 and IFN-γ Facilitates Inducing TGF-β-induced CD4(+)Foxp3(+) Regulatory Cells.

Type-1 interferon induced cross-regulation of IL-10 function: a novel mechanism in type 1 diabetes development

IFN-β Regulates Th17 Differentiation Partly Through the Inhibition of Osteopontin in Experimental Autoimmune Encephalomyelitis.

Itk Signaling Via the Ras/Irf4 Pathway Regulates the Development and Function of Type 1 Regulatory T Cells

Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b+ myeloid cells

Independent and Interdependent Immunoregulatory Effects of IL-27, IFN-β, and IL-10 in the Suppression of Human Th17 Cells and Murine Experimental Autoimmune Encephalomyelitis.

TGFβ1 Transduction Enhances Immunomodulatory Capacity of Neural Stem Cells in Experimental Autoimmune Encephalomyelitis